Aktis Oncology, Inc. (AKTS) Stock Price & Analysis
Aktis Oncology, Inc. (AKTS) fell 0.50% to USD 23.89 as of July 25, 2026 at 07:24 UTC, according to Nexqual real-time market data.
AKTS last closed at USD 24.01; the session ranged USD 23.4–24.58 on volume of 193,643 shares. Market capitalization is $1.32B, with a 52-week range of USD 14.72–34.19 (NMS). Source: Nexqual, July 25, 2026 at 07:24 UTC.
Key Statistics (as of July 25, 2026 at 07:24 UTC)
| Price | USD 23.89 |
|---|---|
| Change | ▼ 0.50% (down) |
| Previous Close | USD 24.01 |
| Open | USD 24.06 |
| Day Range | USD 23.4 – 24.58 |
| 52-Week Range | USD 14.72 – 34.19 |
| Volume | 193,643 shares |
| Market Cap | $1.32B |
| Exchange | NMS |
Technical Analysis (AKTS)
Nexqual's technical model rates AKTS "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 07:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.7 (neutral) |
| vs SMA50 | Above (USD 23.52) |
| MACD | -0.1 (negative) |
Analyst Ratings (AKTS)
Wall Street analysts rate AKTS "Strong Buy" based on 6 analysts, with a mean price target of USD 34.38 (range USD 31.25–40), per Nexqual as of July 25, 2026 at 07:24 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 34.38 |
| High Target | USD 40 |
| Low Target | USD 31.25 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (AKTS)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.43 |
| Revenue Estimate | $2.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.38 vs est -0.33 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:24 UTC.
Financials & Fundamentals (AKTS)
| Total Revenue | $8.28M |
|---|---|
| Revenue Growth (YoY) | +123.00% |
| Gross Margin | +0.00% |
| Operating Margin | -703.63% |
| Profit Margin | +0.00% |
| Debt / Equity | 2.29 |
| Current Ratio | 19.49 |
| Total Cash | $538.48M |
| Total Debt | $11.58M |
Source: Nexqual, July 25, 2026 at 07:24 UTC.
Financial Health Score (AKTS)
Nexqual rates Aktis Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:24 UTC.
| Growth | Strong — Revenue +123% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $538M cash vs $12M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$71M |
| Efficiency | Mixed — No data |
Ownership (AKTS)
| Insider Ownership | +14.14% |
|---|---|
| Institutional Ownership | +74.41% |
| Shares Outstanding | 53.40M |
| Float | 28.15M |
| Short % of Float | +23.64% |
Source: Nexqual, July 25, 2026 at 07:24 UTC.
Leadership (AKTS)
Aktis Oncology, Inc. is led by Matthew Roden, President, CEO & Director, per Nexqual as of July 25, 2026 at 07:24 UTC.
| President, CEO & Director | Matthew Roden |
|---|---|
| Co-Founder & Chairman | Todd Foley (age 53) |
| Chief Scientific Officer | Paul L. Feldman (age 63) |
| Chief Financial Officer | Kyle D. Kuvalanka (age 57) |
| Chief Operating Officer | Shulamit Ron-Bigger (age 44) |
Major Backers & Investors (AKTS)
Notable institutional backers of Aktis Oncology, Inc. include MPM Bioimpact LLC, EcoR1 Capital, LLC, T. Rowe Price, according to Nexqual as of July 25, 2026 at 07:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 9.06% |
| EcoR1 Capital, LLC | 9.03% |
| T. Rowe Price | 6.35% |
| Blue Owl Capital Holdings LP | 5.92% |
| Wellington Management | 4.34% |
| Price (T.Rowe) Associates Inc | 3.53% |
| RTW Investments LP | 2.98% |
| RA Capital Management, L.P. | 2.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.37% |
| Vanguard Group | 4.92% |
Source: Nexqual, July 25, 2026 at 07:24 UTC.
From Aktis Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
- The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
- It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | USD 1.19 | ▼ 6.3% |
| DTIL | Precision BioSciences, Inc. | USD 7.29 | ▼ 0.41% |
| INSG | Inseego Corp. | USD 6.66 | ▼ 10.48% |
| AIRG | Airgain, Inc. | USD 5.86 | ▼ 1.18% |
| ATOM | Atomera Incorporated | USD 5.18 | ▼ 10.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:24 UTC. This page is informational and not investment advice.